Continuous processing of monoclonal antibodies (mAb) could offer a number of advantages, but regulatory uncertainty and upfront investment remain sticking points.
In this case study, Shanghai Henlius Biotech describes its approach to continuous mAb bioprocessing. Insights, experiences, and challenges addressed from their implementation are shared.
Click here to read the article.